glp-1 agonist and dpp-4 inhibitor receptor versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes GLP-1-based therapies, including GLP-1, GLP-1R

T.A.is supported by an NIHR Senior Clinical and Practitioner Award and reports institutional grants or contracts from Nova Pharmaceuticals, Astra-Zeneca

Under pathological stress, macrophages contribute to inflammatory responses, which drive insulin resistance and T2DM

Despite the small sample size (only 10 patients), the observed benefits suggest that GLP-1RAs could have a therapeutic role in PsA through inflammation reduction, similar to what had been observed in PsO (61)

However, oral formulations represent the most significant route-specific innovation, with the potential to expand the market by addressing injection anxiety and enabling primary care prescribing without specialized training

Baggio, L

This was consistent between the sexes